ALPS Advisors’s CytomX Therapeutics CTMX Stock Holding History

ALPS Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$402K	Buy	107,100 +1,280	+1%	+$4.89K	﹤0.01%	1046
2026 Q1	$497K	Buy	+105,820	New	+$537K	﹤0.01%	835
2022 Q2	–	Sell	-67,211	Closed	-$179K	–	1046
2022 Q1	$179K	Sell	67,211 -8,302	-11%	-$31.9K	﹤0.01%	809
2021 Q4	$327K	Sell	75,513 -4,340	-5%	-$25.4K	﹤0.01%	811
2021 Q3	$406K	Sell	79,853 -5,776	-7%	-$30.9K	﹤0.01%	538
2021 Q2	$542K	Buy	85,629 +2,000	+2%	+$15.6K	﹤0.01%	506
2021 Q1	$646K	Buy	83,629 +136	+0.2%	+$1.08K	0.01%	463
2020 Q4	$547K	Buy	+83,493	New	+$596K	0.01%	482
2020 Q2	–	Sell	-82,601	Closed	-$634K	–	791
2020 Q1	$634K	Sell	82,601 -9,632	-10%	-$67.2K	0.01%	402
2019 Q4	$766K	Buy	+92,233	New	+$622K	0.01%	423

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

ALPS Advisors's CTMX Position: Q2 2026 in Review

ALPS Advisors increased its CytomX Therapeutics (CTMX) stake by 1.2% in Q2 2026, buying an estimated $4.89K and bringing the position to 107,100 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #1046.

ALPS Advisors first reported a position in CTMX in Q4 2019 and has held it in 10 quarters since. The position peaked at $766K in Q4 2019. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

ALPS Advisors held 107,100 shares of CytomX Therapeutics worth $402K as of Q2 2026.
ALPS Advisors bought 1,280 CytomX Therapeutics shares in Q2 2026, an estimated $4.89K.
CytomX Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1046 holding.
ALPS Advisors first reported a position in CytomX Therapeutics in Q4 2019 and has held it in 10 quarters since.
ALPS Advisors's CytomX Therapeutics position peaked at $766K in Q4 2019.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.